Hepatitis, Alcoholic
Welcome,         Profile    Billing    Logout  
 6 Companies   5 Products   5 Products   4 Mechanisms of Action   0 Trials   74 News 


12»
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date:  Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD (clinicaltrials.gov) -  Jun 12, 2018   
    P3,  N=151, Active, not recruiting, 
    Trial completion date: Mar 2023 --> Sep 2018 | Active, not recruiting --> Terminated; VTL-308 failed to meet its primary endpoint, all follow up studies were terminated Recruiting --> Active, not recruiting | Trial completion date: Mar 2018 --> Mar 2023 | Trial primary completion date: Dec 2017 --> Mar 2018
  • ||||||||||  emricasan (IDN 6556) / Histogen, Amerimmune
    Trial primary completion date:  Study of IDN-6556 in Patients With Severe AH and Contradictions to Steroid Therapy (clinicaltrials.gov) -  Sep 25, 2015   
    P2,  N=5, Terminated, 
    N=150 --> 18 | Recruiting --> Terminated | Trial primary completion date: May 2016 --> Oct 2015; Due to results from the VTI-208 study, the ELAD plan is being re-evaluated. Trial primary completion date: Nov 2014 --> Aug 2015
  • ||||||||||  emricasan (IDN 6556) / Histogen, Amerimmune
    Trial primary completion date:  Study of IDN-6556 in Patients With Severe AH and Contradictions to Steroid Therapy (clinicaltrials.gov) -  Jul 15, 2015   
    P2,  N=5, Terminated, 
    Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Apr 2015 Trial primary completion date: May 2015 --> Nov 2014
  • ||||||||||  emricasan (IDN 6556) / Histogen, Amerimmune
    Enrollment change, Trial termination:  Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF (clinicaltrials.gov) -  Apr 30, 2015   
    P2,  N=23, Terminated, 
    Trial primary completion date: Jun 2015 --> Jun 2016 N=60 --> 23 | Active, not recruiting --> Terminated; Data needs met
  • ||||||||||  emricasan (IDN 6556) / Histogen, Amerimmune
    Enrollment change, Trial termination, Trial primary completion date:  Study of IDN-6556 in Patients With Severe AH and Contradictions to Steroid Therapy (clinicaltrials.gov) -  Feb 12, 2015   
    P2,  N=5, Terminated, 
    Trial primary completion date: Mar 2015 --> Jun 2015 N=60 --> 5 | Recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Apr 2015; Emerging data indicated 25mg may not be adequate in very severe hepatic impairment subjects despite higher exposures and that additional dose-ranging was needed
  • ||||||||||  metadoxine / Generic mfg.
    Trial completion:  Metadoxine as a Therapy for Severe Alcoholic Hepatitis (clinicaltrials.gov) -  Nov 12, 2014   
    P4,  N=135, Completed, 
    Initiation date: Mar 2015 --> Mar 2014 Active, not recruiting --> Completed
  • ||||||||||  emricasan (IDN 6556) / Histogen, Amerimmune
    Enrollment closed, Trial primary completion date:  Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF (clinicaltrials.gov) -  Oct 2, 2014   
    P2,  N=60, Active, not recruiting, 
    N=120 --> 150 | Trial primary completion date: Feb 2015 --> May 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Nov 2014
  • ||||||||||  Trial suspension:  SETH-HA: Liver Transplantation in Alcoholic Hepatitis (clinicaltrials.gov) -  Jun 1, 2014   
    P=N/A,  N=40, Suspended, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Nov 2014 Not yet recruiting --> Suspended